Deals In Depth: November 2022

Five $1bn+ alliances were penned in November. Topping the list was a potential $4.5bn deal between Arcturus Therapeutics and CSL Seqirus.  

Deals In Depth

Topping the list of November alliances was a potential $4.5bn deal between Arcturus Therapeutics Ltd. and CSL Seqirus.

Under the agreement, Arcturus will provide CSL Seqirus with a license to its self-amplifying mRNA technology to support the research,...

More from Deal-Making

More from In Vivo